

Scientific Biosketch

Prof. Dr. med. Dr. h. c. Rüdiger Hehlmann, chief of medicine at the Mannheim Medical Faculty of Heidelberg University until 2007, founded in cooperation with his colleagues the German CML Study Group in 1982, the German Competence Network for Acute and Chronic Leukemias in 1997 and the European LeukemiaNet (ELN) in 2002. He is past president of the German Society of Hematology and Oncology, past Dean of his faculty and past Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases (IACRLRD). He is honorary member of the Polish and German Societies for Hematology and Oncology. He completed his last randomized CML study (CML Study IV) in 2017 and currently manages the ELN Foundation in support of ELN.



10 Selected Publications (2016- 2018)

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, **Hehlmann R**, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.

Saussele S, **Hehlmann R**, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. *Leukemia*. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

Hehlmann R. Advancing a field by building consortia: The example of the European LeukemiaNet. *Cancer*. 2018 Mar 15;124(6):1100-1104. doi: 10.1002/cncr.31199. Epub 2018 Feb 16.

Hehlmann R, Lauseker M, Sauße S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year

survival results of the randomized CML study IV and impact of non-CML determinants. *Leukemia*. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

Khoury HJ, Williams LA, Atallah E, **Hehlmann R**. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. *Am Soc Clin Oncol Educ Book*. 2017;37:468-479. doi: 10.14694/EDBK_175712.

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, **Hehlmann R**. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2017 Jul;143(7):1311-1318. doi: 10.1007/s00432-017-2385-7. Epub 2017 Mar 8.

Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, **Hehlmann R**, Pfirrmann M; German CML Study Group. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. *Cancer*. 2017 Jul 1;123(13):2467-2471. doi: 10.1002/cncr.30636. Epub 2017 Feb 13.

Hehlmann R, Sauße S, Voskanyan A, Silver RT. Management of CML-blast crisis. *Best Pract Res Clin Haematol*. 2016 Sep;29(3):295-307. doi: 10.1016/j.beha.2016.10.005. Review.

Hehlmann R. Innovation in hematology. Perspectives: CML 2016. *Haematologica*. 2016 Jun;101(6):657-9.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, **Hehlmann R**, Clark RE. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*. 2016 Jun 3. doi: 10.1038/leu.2016.104. [Epub ahead of print] Review.